Muscle protein degradation

"Muscle protein degradation" is not a single molecule, receptor, or canonical drug target, but rather refers to the collective biological processes by which proteins within skeletal muscle are broken down. This occurs primarily through two major proteolytic systems: 1. Ubiquitin-proteasome system (UPS): - The main pathway responsible for targeted degradation of damaged or unneeded proteins in skeletal muscle. - Involves tagging substrate proteins with polyubiquitin chains via sequential action of E1 (activating), E2 (conjugating), and E3 (ligase) enzymes. - Key E3 ligases such as Atrogin-1/MAFbx and MuRF1 are upregulated during conditions that induce muscle wasting and serve as markers for increased proteolysis[2][8]. - The tagged proteins are recognized by the 26S proteasome complex and degraded into peptides/amino acids[2][6]. 2. Autophagy–lysosome pathway: - Degrades larger structures like organelles and aggregated proteins via lysosomal digestion. - Works in concert with UPS; some substrates may be directed preferentially to one system or another depending on their ubiquitination pattern[4][5]. Other contributing systems include calpains and caspases that initiate myofibrillar disassembly before further breakdown by UPS or autophagy[4][7]. Muscle protein degradation is regulated by multiple signaling pathways, including insulin/IGF-I/protein kinase B axis, glucocorticoids, TNF-alpha, myostatin, oxidative stressors, etc.[1][4]. Dysregulation leads to pathological states such as sarcopenia (age-related loss), cachexia in chronic illness/cancer/sepsis, disuse atrophy from immobilization/microgravity exposure. Because "muscle protein degradation" describes a process involving many molecular players, it is not considered an individual therapeutic target but rather an area where specific components—such as certain E3 ligases—may be targeted pharmacologically. Summary: The term "muscle protein degradation" does not refer to a discrete molecule/receptor but instead encompasses several coordinated enzymatic pathways responsible for breaking down skeletal muscle proteins under physiological and pathological conditions. As such it should not be listed as a canonical drug target; more precise targets would include key regulatory enzymes like Atrogin-1/MAFbx or MuRF1 within these pathways[2][8].

Other names

Muscle protein breakdownSkeletal muscle proteolysisMuscle atrophy (as a process)